| 1) Development of curative treatments for gli |
| 2) Conclusions: Development of small molecule Bak activato |
| 3) Development of these techniques, especiall |
| 4) Development of treatment protocols specifi |
| 5) sting the involvement of miR-195 in early development of AD with a potential impact |
| 6) form of vitamins A, C, and E, prevent the development of ARHL. |
| 7) the extracted mouse eye DNA confirmed the development of Acanthamoeba-induced kerati |
| 8) ns (APOs) may play important roles in the development of Alzheimer's disease (AD) an |
| 9) ther-related variables or seasons and the development of Bell's palsy (BP) is contro |
| 10) r biomarkers exist to help us predict the development of CI and understand its biolo |
| 11) ective and increased concerns about rapid development of COVID-19 vaccines. |
| 12) valuate the association of anaemia on the development of DM and major clinical outco |
| 13) ia was associated with higher rate of the development of DM and mortality during 5-y |
| 14) The primary endpoint was the development of DM. |
| 15) tained NF-κB signaling essential for the development of ER-negative breast cancer. |
| 16) nt a new horizon as potential targets for development of FASD therapy. |
| 17) Background data on the development of HS mice is provided, includ |
| 18) minated urine are etiological factors for development of IAD. |
| 19) Autoantibodies track with longitudinal development of IgG antibodies recognizing |
| 20) In addition, the development of LeishGEdit, a PCR-based too |
| 21) To inform further development of NMAs, we conducted a biblio |
| 22) studies (n = 20) involved patients in the development of PILs, in the assessment of |
| 23) healing (pulp survival) and the possible development of PN after PCO. |
| 24) groundwater quality management including development of Quantitative Microbial Risk |
| 25) ied in this study can be used for further development of RI promotion practices in R |
| 26) ferent genetic components involved in the development of SCZ. |
| 27) ur objective was to explore the scope and development of SHP in Cameroon. |
| 28) In relation with the development of VSM, a heterogeneity in the |
| 29) rtant considerations and elements for the development of a common evaluation framewo |
| 30) rovide some guidance to better inform the development of a context-fit stroke model |
| 31) cal education fellowships, and inform the development of a core curriculum shared ac |
| 32) We suggest that the development of a core outcome set could im |
| 33) In the future, we recommend the development of a core set of psychological |
| |